Precision Health Research, Singapore (PRECISE) announced a precompetitive collaboration with Alnylam, Bayer, Boehringer Ingelheim and Novo Nordisk to analyze data from the PRECISE‑SG100K population cohort. The partners will use whole‑genome and proteomic datasets to investigate Asian-specific genetics, disease risk and biomarkers. PRECISE will provide the genomic and clinical datasets while partners will support analytics, AI tools and research activities. The collaboration aims to fill diversity gaps in genomic research and accelerate discoveries tailored to Asian populations. The deal signals increasing pharma engagement in national-scale genomic programs and sets the stage for Asia-focused target discovery, biomarker development and potential clinical translation.